Compare Gilead Sciences, Inc. (GILD) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs QUALCOMM, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.77 (market cap $168.35B), while QUALCOMM, Inc. trades at $166.25 (market cap $170.81B). The key difference: Gilead Sciences, Inc. and QUALCOMM, Inc. are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | QCOM | |
|---|---|---|
Market Cap | $168.35B | $170.81B |
Sector | Health | Technology |
52-Week High | $155.80 | $251.10 |
52-Week Low | $110.56 | $124.07 |
Enterprise Value | $191.42B | $177.78B |
Dividend Yield | 2.42% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Qualcomm (QCOM) trades at $162.17, down 3.39% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue of $44.28B in 2025 but saw net income decline to $5.54B, reflecting margin pressures. Recent news highlights Qualcomm's AI and data center expansion efforts, including the 'Dragonfly' AI platform announcement at COMPUTEX 2026, while facing increased competition from Nvidia in the PC chip market.
The outlook remains balanced with a consensus price target of $200.56 suggesting 24% upside, but near-term headwinds include smartphone market softness and margin compression. Long-term growth drivers in automotive and AI inference markets provide opportunity, though execution risks and competitive threats from chip rivals pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
